BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering treatments for patients with genetic diseases and significant unmet medical needs. Operating through a decentralized hub-and-spoke model, the company organizes program-specific development units supported by centralized operational and regulatory infrastructure. Its primary commercial product is acoramidis, a small molecule transthyretin stabilizer branded as Attruby in the United States and Beyonttra internationally for transthyretin amyloid cardiomyopathy. The enterprise also holds approved therapies such as Nulibry and advances late-stage clinical programs including infigratinib for skeletal conditions and encaleret for calcium regulation disorders. Its offerings serve patient populations diagnosed with rare genetic conditions through specialized medical treatment centers and healthcare practitioners.

The company distributes its lead treatment in the United States directly through a specialized network of specialty distributors, pharmacies, and approved hospital systems. Internationally, commercial activities reach patients through strategic collaboration partners, including Bayer across European territories and Alexion in Japan, alongside direct commercialization in selected markets. BridgeBio conducts business operations across the United States, Europe, and Asia, relying entirely on third-party contract organizations for product manufacturing.

Summary of the business section of BridgeBio Pharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 834 full-time employees and 5 part-time employees.”